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Background: The phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy
of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall
survival, the primary endpoint. In the MPACT trial, patients were treated until progressive disease (PD) or
unacceptable toxicity. The current exploratory analysis investigated outcomes of patients from the MPACT trial who
were treated until PD, in order to understand how to maximize treatment benefit from nab-P + Gem.
Methods: The trial design has been described in detail previously. Progressive disease was determined by the
investigator on the basis of radiological imaging.
Results: Among patients who were treated until PD, overall survival was significantly longer for those who received
nab-P + Gem vs Gem (median, 9.8 vs 7.5 months; P < 0.001). Independently assessed progression-free survival and
overall response rate were significantly greater among patients in the treatment-to-PD cohort who received nab-P
+ Gem compared with Gem (P < 0.001 for each). Although not compared statistically, patients who were treated
until PD received greater treatment exposure and experienced more favourable efficacy than the intent-to-treat
population of the MPACT trial. Among patients who were treated with nab-P + Gem until PD, > 50 % went on to
receive a subsequent therapy. The safety profile for patients treated until PD was similar to what was reported in
the overall MPACT trial.
Conclusion: The nab-P + Gem regimen is an active first-line treatment option; most patients were treated until PD,
and this exposure was associated with improved efficacy outcomes. Prolonged first-line treatment exposure and
ability to receive subsequent therapies likely contributed to the improved survival among these patients. Our data
highlight the importance of managing adverse events and indicate that patients should be treated until PD when
possible.
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Trial registration: ClinicalTrials.gov NCT00844649 (MPACT trial); Registration date of this prospective phase III trial:
February 13, 2009; current exploratory subanalysis was conducted retrospectively.
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Worldwide pancreatic cancer mortality and incidence
rates are nearly equal [1]. In the United States and
Europe, pancreatic cancer is the fourth leading cause of
cancer-related mortality, with a 5-year survival rate of
7 % to 8 % among patients with all disease stages [2–4].
Surgical resection offers the only curative treatment for
pancreatic cancer; however, only 15 % to 20 % of
patients are candidates for surgery at diagnosis [5]. Even
when an R0 resection is achieved, many patients will
relapse within 2 years, and it is likely that distant
micrometastases have already been established in
the ≈ 15 % to 20 % of patients believed to be surgery
candidates [6, 7]. According to the Surveillance, Epidemi-
ology, and End Results Program, 52 % of patients with
pancreatic cancer are diagnosed with metastatic disease,
which portends a 2.6 % 5-year survival rate [4].
At the metastatic stage, the goals of treatment are to
palliate symptoms and prolong survival [7]. Since the
phase 3 trial nearly 20 years ago [8] that led to the
approval of gemcitabine (Gem), numerous phase 3 trials
of Gem combination regimens have failed to demonstrate
a clinically and statistically significant survival benefit
compared with Gem monotherapy in patients with
metastatic pancreatic cancer [9–16]. Recently, 2 regimens,
FOLFIRINOX (folinic acid + 5-fluorouracil [5-FU] + irino-
tecan + oxaliplatin) and nab-paclitaxel (nab-P) + Gem,
demonstrated significantly longer survival compared with
Gem alone [17–19]. The phase 3 MPACT trial (Clinical-
Trials.gov NCT00844649) demonstrated superior efficacy
of nab-P +Gem compared with Gem alone for all trial
endpoints, including the primary endpoint, overall sur-
vival (OS; median, 8.7 vs 6.6 months; hazard ratio [HR],
0.72; P < 0.001) in patients with metastatic pancreatic
cancer and Karnofsky performance status ≥ 70 [18, 19]. In
the MPACT trial, grade ≥ 3 adverse events (AEs) were
effectively managed by dose reductions and delays.
Although results from the phase 3 PRODIGE and
MPACT trials were encouraging [17, 19], the regimens
are not recommended for all patients with metastatic
pancreatic cancer. A retrospective analysis found that
75 % of real-world patients with metastatic pancreatic
cancer did not meet the PRODIGE trial inclusion
criteria, with performance status, age, and elevated
bilirubin levels being the main reasons for ineligibility
[20]. The inclusion criteria of the MPACT trial [18]allowed for nab-P + Gem to be administered to a wider
range of patients, including older patients or those with
poorer performance status. Because nab-P + Gem has
now become the most commonly used first-line chemo-
therapy option for patients with metastatic pancreatic
cancer in the United States [21], it is important to better
understand how to achieve the optimal benefit with this
regimen. Per protocol, patients in MPACT were treated
until progressive disease (PD) or unacceptable toxicity.
The current exploratory analysis investigated character-
istics and outcomes of patients who were treated until
PD as assessed by radiological imaging.Methods
Study design
Study design and patient eligibility of the phase 3
MPACT trial were described previously [18]. Patients
were randomly assigned 1:1 to either intravenous nab-P
125 mg/m2 followed by intravenous Gem 1000 mg/m2
once weekly for the first 3 weeks of a 4-week cycle or
Gem 1000 mg/m2 for the first 7 weeks of an 8-week
cycle (cycle 1) and subsequently the first 3 weeks of a
4-week cycle (cycle ≥ 2). Per protocol, patients were
treated until either PD or an unacceptable level of AEs.
Tumour response was evaluated every 8 weeks using
spiral computed tomography or magnetic resonance im-
aging. The aim of the present analysis was to determine
the characteristics and outcomes of patients who were
treated until PD during the phase 3 MPACT trial.
The PD cohort consisted of patients who experienced
disease progression as declared by the investigator on
the basis of computed tomography or magnetic reson-
ance imaging and excluded patients who received further
therapy. These patients also may have experienced a
treatment-limiting toxicity at the time of PD. As a
comparator group, patients who discontinued treatment
due to AEs in the absence of PD were also analysed.Subsequent therapy use
Data on subsequent therapies included only the dates
and type of treatment administered. For patients who
received FOLFOX (folinic acid + 5-FU + oxaliplatin) or
OFF (oxaliplatin + folinic acid + 5-FU), data were com-
bined because information regarding dosing and sched-
ule were unknown.
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The Kaplan-Meier method was used to determine OS,
and a stratified log-rank test was used to assess statis-
tical significance. In the case of patients who were lost
to follow-up, survival data were censored at the last date
at which they were known to be alive. The results
presented herein are based on the updated cutoff date
for OS analysis, which was 9 May 2013. Progression-free
survival (PFS) was compared between the treatment
arms using the Kaplan-Meier method, and differences
were tested using a stratified log-rank test. For the OS
and PFS analysis, the HR and 95 % CI calculation used
the proportional hazard assumption. Differences in
overall response rate (ORR) were assessed by χ2 test.Results
Baseline characteristics
In general, the baseline characteristics of patients treated
to PD or AEs in the absence of PD were well balanced
and similar to those of the intent-to-treat (ITT) popula-
tion (Table 1). Although differences in baseline charac-
teristics between the cohorts were not compared
statistically, some minor imbalances were noted. Among
patients treated with nab-P + Gem, those in the
treatment-to-AEs cohort were older than those in the
treatment-to-PD cohort or ITT population. Patients who
received Gem alone in the treatment-to-AEs cohort had
a greater metastatic burden compared with all otherTable 1 Baseline characteristics of patients treated to disease progre
the intent-to-treat population





Age, median, years 61.0 63.0
≥ 65 years, % 39 42
Male, %, KPS, % 60 58
90 %-100 % 60 67
70 %-80 % 40 33
Current site(s) of metastasis, %
Lung 33 40
Liver 90 84





Previous Whipple procedure, % 8 7
Biliary stent, % 21 15
AE adverse event, Gem gemcitabine, ITT intent to treat, KPS Karnofsky performancecohorts. Fewer patients in the treatment-to-AEs cohort
underwent a previous Whipple procedure compared
with those in the treatment-to-PD cohort and the ITT
population. Among patients who were treated with Gem
monotherapy, more patients in the treatment-to-AEs co-
hort had a biliary stent at baseline compared with those
in the treatment-to-PD cohort and the ITT population.Efficacy
Overall survival
Overall survival in the treatment-to-PD cohort was sig-
nificantly longer for patients who received nab-P + Gem
compared with those who received Gem alone (median,
9.8 vs 7.5 months; HR, 0.69; P < 0.001; Fig. 1).
Kaplan-Meier estimates of OS rate at 24 months follow-
ing randomization were 8 % for nab-P + Gem compared
with 4 % for Gem alone among patients in the
treatment-to-PD cohort. The OS data in the treatment-
to-PD cohort were based on 419 events (92 %), including
206 and 213 in the nab-P + Gem (92 %) and Gem-alone
(91 %) arms, respectively.
Overall survival in the treatment to AEs cohort was
numerically, but not significantly, longer for patients
who received nab-P + Gem compared with those who
received Gem alone (median, 7.7 vs 6.0 months; HR,
0.87; P = 0.466; Table 2 [based on 136 events; 87 %]).
Kaplan-Meier estimates of OS rates at 24 months
following randomization were 14 % for nab-P + Gemssion, adverse events in the absence of disease progression, and









66.5 63.5 62.0 63.0
55 48 41 44
58 66 57 60
58 57 58 62
41 43 42 38
38 52 35 43
84 79 85 84
7 3 8 5
47 41 47 48
32 31 32 33
14 24 14 15
3 3 7 7
17 28 19 16
status, nab-P nab-paclitaxel, PD progressive disease
Fig. 1 Overall survival in patients treated to disease progression. Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel
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the treatment-to-AEs cohort.Progression-free survival
In patients treated to PD, PFS was significantly longer
for patients treated with nab-P + Gem compared with
those who received Gem alone (median, 6.0 vs
3.8 months; HR, 0.62; P < 0.001; Fig. 2). In patients
treated to AEs, PFS was numerically longer for patients
treated with nab-P + Gem compared with those who
received Gem alone, although this difference did notTable 2 Efficacy in patients treated to disease progression, adverse
treat population





Overall survival, median, months 9.8 7.5
Hazard ratio (95 % CI) 0.69 (0.56–0.84)
P value <0.001
Progression-free survival, median, months 6.0 3.8
Hazard ratio (95 % CI) 0.62 (0.50–0.79)
P value <0.001
Overall response rate, % 27 9
Complete response <1 0
Partial response 26 9
Stable disease 33 35
Response rate ratio (95 % CI) 3.12 (1.95–5.00)
P value <0.001
Disease control ratea 57 40
Disease control rate ratio (95 % CI) 1.42 (1.17–1.72)
P value <0.001
AE adverse event, Gem gemcitabine, ITT intent-to-treat, nab-P nab-paclitaxel, PD pro
aDisease control rate includes patients who achieved a complete or partial response
bBased on 99 evaluable patients
cBased on 59 evaluable patientsreach statistical significance (median, 5.5 vs 5.0 months;
HR, 0.63; P = 0.053).Overall response rate
In the treatment-to-PD cohort, the independently assessed
ORR was significantly higher for patients treated with
nab-P + Gem vs those treated with Gem alone (27 % vs
9 %; response rate ratio [RRR], 3.12; P < 0.001; Table 2).
One patient (<1 %) in the nab-P + Gem arm and 0
patients in the Gem-alone arm achieved a complete re-
sponse (CR). The disease control rate (DCR; CR + partialevents in the absence of disease progression, and the intent-to-










7.7 6.0 8.7 6.6
0.87 (0.60–1.27) 0.72 (0.62–0.83)
0.466 <0.001
5.5 5.0 5.5 3.7
0.63 (0.40–1.01) 0.69 (0.58–0.82)
0.053 <0.001
19 10 23 7
0 0 <1 0
19 10 23 7
30 34 27 28
1.87 (0.79–4.42) 3.19 (2.18–4.66)
0.137 <0.001
43b 42c 48 33
1.03 (0.71–1.49) 1.46 (1.23–1.72)
0.896 <0.001
gressive disease
or stable disease for ≥ 16 weeks
Fig. 2 Progression-free survival in patients treated to disease progression. Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel
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cantly higher for patients in this cohort who were treated
with nab-P +Gem compared with Gem alone (57 % vs
40 %; RRR, 1.42; P < 0.001).
The independently assessed ORR was numerically
higher for patients in the treatment-to-AEs cohort who
received nab-P + Gem vs Gem alone (19 % vs 10 %;
RRR, 1.87; P = 0.137; Table 2). No patients in either
treatment arm achieved a CR in this cohort. The DCR
was comparable for patients in this cohort who received
nab-P + Gem compared with Gem alone (43 % vs 42 %).
Treatment exposure
The median treatment duration for patients in the
treatment-to-PD cohort was 5.3 months (range, 0.16-
21.9) for nab-P + Gem and 3.6 months (range, 0.13-21.5)
for Gem alone (Table 3). For patients in the treatment-
to-AEs cohort, the median treatment durations wereTable 3 Treatment exposure in patients treated to disease progress
the overall treated population





Treatment duration, median, months 5.3 3.6
nab-P dose intensity, median, mg/m2/week 77.8 —
Gem dose intensity, median, mg/m2/week 626.3 695.9




nab-P doses given at 125 mg/m2, % 72 —
Gem doses given at 1000 mg/m2, % 65 75
Patients with ≥ 1 nab-P dose reduction, n (%) 103 (46) —
Patients with ≥ 1 Gem dose reduction, n (%) 114 (51) 89 (3
Patients with ≥ 1 nab-P dose delay, n (%) 165 (74) —
Patients with ≥ 1 Gem dose delay, n (%) 158 (71) 145 (
AE adverse event, Gem gemcitabine, ITT intent-to-treat, nab-P nab-paclitaxel, PD pro
aBased on 97 evaluable patients2.9 months (range, 0.13-20.7) and 2.3 months (range,
0.16-25.8), respectively (Table 3).
Among patients treated to PD in the nab-P + Gem
arm, 46 % had ≥ 1 nab-P dose reduction and 74 % had ≥
1 nab-P dose delay (Table 3). Similarly, among patients
treated to AEs in the nab-P + Gem arm, 38 % of patients
had ≥ 1 nab-P dose reduction and 73 % had ≥ 1 nab-P
dose delay (Table 3).
Among patients treated to PD in the nab-P + Gem
arm, the percentage of nab-P doses delivered at 125 mg/
m2 and Gem doses delivered at 1000 mg/m2 were 72 %
and 65 %, respectively; 75 % of Gem doses were
delivered at 1000 mg/m2 in the Gem-alone arm (Table 3).
Among patients treated to AEs in the nab-P + Gem arm,
the percentage of nab-P doses delivered at 125 mg/m2
and Gem doses delivered at 1000 mg/m2 were numeric-
ally lower (62 % and 53 %, respectively), and the percent-
age of Gem doses delivered at 1000 mg/m2 in theion, adverse events in the absence of disease progression, and










2.9 2.3 3.9 2.8
61.2 — 74.1 —
523.4a 590.9 597.3 674.9
925 — 1425 —
0 8000a 7500 11,400 9000
62 — 71 —
53 81 63 79
37 (38) — 172 (41) —
8) 48 (49) 19 (33) 198 (47) 132 (33)
72 (73) — 300 (71) —
62) 72 (73) 36 (62) 295 (70) 230 (57)
gressive disease
Table 5 Subsequent therapy use in patients treated to disease
progression





Any subsequent therapy, n (%) 117 (52) 133 (57)
OS, median, months 11.3 9.4
HR (95 % CI) 0.75 (0.57-0.97)
P value 0.027
5-FU/capecitabine based, n (%)a 99 (85) 109 (82)
OS, median, months 11.6 9.2
HR (95 % CI) 0.71 (0.53–0.94)
P value 0.017
FOLFIRINOX (modified/unmodified), n (%)a 14 (12) 18 (14)
OS, median, months 15.3 7.6
HR (95 % CI) 0.45 (0.20–1.00)
P value 0.044
FOLFOX/OFF, n (%)a 27 (23) 37 (28)
OS, median, months 13.5 9.5
HR (95 % CI) 0.58 (0.34–0.98)
P value 0.038
Other, n (%)a 18 (15) 24 (18)
OS, median, months 10.0 10.4
HR (95 % CI) 1.00 (0.53–1.88)
P value >0.999
No subsequent therapy, n (%) 107 (48) 100 (43)
OS, median, months 7.9 5.2
HR (95 % CI) 0.62 (0.46–0.82)
P value <0.001
5-FU 5-fluorouracil, Gem gemcitabine, FOLFIRINOX folinic acid + 5-fluorouracil +
irinotecan + oxaliplatin, FOLFOX folinic acid + 5-fluorouracil + oxaliplatin, nab-P
nab-paclitaxel, OFF oxaliplatin + folinic acid + 5-fluorouracil, OS overall survival,
PD progressive disease
aFor specific examples of subsequent therapies, percentages are calculated
using the number of patients who received a subsequent therapy as
the denominator
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Cumulative doses are described in detail in Table 3.
Reasons for treatment discontinuation
The AEs that most commonly led to treatment discon-
tinuation are summarized in Table 4. Among patients in
the treatment-to-AEs cohort who received nab-P + Gem,
the most common AEs that led to treatment discontinu-
ation were peripheral neuropathy and fatigue. Among
patients in the treatment-to-AEs cohort who received
Gem alone, the most common AE that lead to treatment
discontinuation was thrombocytopenia.
Subsequent therapy use
Within the treatment-to-PD cohort, the use of subse-
quent therapy in the nab-P + Gem and Gem-alone arms
was 52 % and 57 %, respectively, and these patients had
numerically longer OS (median, 11.3 and 9.4 months,
respectively; Table 5) than all patients in this cohort
(median, 9.8 and 7.5 months, respectively; Fig. 1 and
Table 2). In both arms of the treatment-to-PD cohort,
5-FU– or capecitabine-based regimens were the most
commonly used subsequent therapies, with the majority
of these patients having received a 5-FU–based regimen.
Among patients who were treated to AEs, the majority
(73 % and 74 % of those in the nab-P + Gem and
Gem-alone arms, respectively) did not receive a subse-
quent therapy; therefore, OS was not reported for these
patients.
Safety
Incidences of grade ≥ 3 hematologic AEs in both cohorts
were similar to those reported in the MPACT trial, al-
though there were higher rates of anaemia among pa-
tients treated to AEs in both treatment arms compared
with the treated population of the MPACT trial [18].
Among patients treated to PD, nab-P + Gem, compared
with Gem alone, had slightly higher rates of neutropenia
(39 % vs 31 %) and thrombocytopenia (13 % vs 9 %) butTable 4 Most common adverse events that led to treatment
discontinuationa




Peripheral neuropathy 17 (17) 0
Fatigue 11 (11) 2 (3)
Thrombocytopenia 7 (7) 7 (12)
Pneumonia 5 (5) 3 (5)
Pulmonary embolism 2 (2) 5 (9)
Vomiting 2 (2) 3 (5)
Cerebrovascular accident 0 3 (5)
Gem gemcitabine, nab-P nab-paclitaxel
aMost frequent was defined as those adverse events occurring in ≥ 5 % of the
patients in either treatment armnot anaemia (14 % each; Table 6). Among patients
treated to AEs, nab-P + Gem, compared with Gem alone,
had higher rates of neutropenia (40 % vs 27 %), but rates
of anaemia (19 % vs 18 %) and thrombocytopenia (14 %
each) were similar (Table 6). Febrile neutropenia oc-
curred in 2 % of patients in each treatment arm of the
treatment-to-PD cohort and in 4 % and 2 % of patients
who received nab-P + Gem and Gem alone, respectively,
in the treatment-to-AEs cohort (Table 6).
Incidences of grade ≥ 3 nonhematologic AEs in both
cohorts were generally similar to those reported in the
MPACT trial, although fatigue occurred more frequently
among patients who received nab-P + Gem in the
treatment-to-AEs cohort vs the treated population of the
MPACT trial [18]. In both cohorts, rates of fatigue,
Table 6 Adverse events in patients treated to disease progression, adverse events in the absence of disease progression, and the
overall treated population
Grade≥ 3 AEs, % Patients treated to PD Patients treated to AEs All treated patients [18]
nab-P + Gem Gem nab-P + Gem Gem nab-P + Gem Gem
Haematologica n = 223 n = 233 n = 91 n = 56 n = 405 n = 388
Neutropenia 39 31 40 27 38 27
Leukopenia 29 18 41 21 31 16
Thrombocytopenia 13 9 14 14 13 9
Anaemia 14 14 19 18 13 12
Febrile neutropeniab 2 2 4 2 3 1
Nonhaematologicc n = 224 n = 233 n = 98 n = 58 n = 421 n = 402
Fatigue 15 5 29 10 17 7
Peripheral neuropathyd 19 1 21 0 17 1
Diarrhoea 6 2 11 3 6 1
aBased on laboratory values (some missing values)
bPercentages were calculated using the n's reported for nonhaematologic AEs
cBased on investigator assessment of treatment-related events
dGrouped AE term
AE adverse event, Gem gemcitabine, ITT intent to treat, nab-P nab-paclitaxel, PD progressive disease
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nab-P + Gem vs Gem alone (Table 6). The frequency of
grade 2 peripheral neuropathy was similar for patients
who received nab-P + Gem in the treatment-to-PD
cohort, treatment-to-AEs cohort, and overall MPACT
treated population (16 %, 13 %, and 15 %, respectively).
Discussion
This subanalysis provides evidence that the nab-P +
Gem combination is an active first-line treatment option
with significant clinical efficacy for patients with meta-
static pancreatic cancer because the majority of patients
were treated until PD, which was associated with longer
survival compared with the ITT population. Treatment
until PD allowed better efficacy (as assessed by OS and
disease control), likely due to the longer treatment
duration and greater treatment exposure these patients
received compared with those in the ITT population
[18]. In addition, more than half of the patients who
were treated to PD received a subsequent therapy, indi-
cating that nab-P + Gem was also a feasible first-line op-
tion on which a treatment plan can be built. Conversely,
≈ 20 % of patients in the study discontinued treatment
due to AEs in the absence of PD, which limited their
treatment exposure and potential efficacy benefit.
A detailed examination revealed interesting differences
in the relationships of reason for discontinuation, treat-
ment exposure, and efficacy between the 2 treatment
arms. Among patients who received nab-P + Gem, there
was greater efficacy in terms of OS, PFS, and ORR
between patients treated until PD vs the ITT population.
Conversely, although there was a survival benefit in the
Gem-alone arm between patients treated until PD vs theITT population, the difference in PFS and ORR between
the 2 cohorts was modest. The difference in treatment
duration between patients treated until PD and the overall
treated population was numerically longer for those who
received nab-P + Gem compared with Gem alone (1.4 vs
0.8 months). The cumulative Gem dose in the PD cohort
was 14 % and 11 % higher than that in the overall treated
population for the nab-P +Gem and Gem-alone arms, re-
spectively; however, the cumulative nab-P dose was 22 %
higher for the PD cohort than the overall treated cohort
for the combination arm (Table 3). These data raise the in-
triguing but speculative question of whether exposure to
nab-P vs Gem imparts a greater relative treatment benefit.
Adverse events associated with chemotherapy are
routinely managed by dose modification. A post hoc ana-
lysis of patients who underwent dose reductions or delays
in the MPACT trial demonstrated that OS was significantly
longer for those with vs without dose modifications [22].
Thus, mitigating AEs associated with nab-P +Gem through
dose modification is not detrimental to treatment efficacy.
The present analysis reveals that patients who were treated
until PD had more dose reductions and delays compared
with those in the ITT population, which suggests that
effective treatment management may have allowed them to
continue to receive and benefit from therapy.
The most common reasons for discontinuation due to
AEs in the combination arm were peripheral neur-
opathy, fatigue, and thrombocytopenia. Rates of grade 3
peripheral neuropathy were relatively similar among
patients treated to PD or AEs and the overall treated
population, as were rates of grade 2 peripheral neur-
opathy. Management of peripheral neuropathy is accom-
plished by pausing treatment or reducing the treatment
Vogel et al. BMC Cancer  (2016) 16:817 Page 8 of 10dose. Interestingly, in the MPACT trial, OS was signifi-
cantly longer among patients who developed grade 3
peripheral neuropathy vs those who did not develop per-
ipheral neuropathy [23]. Furthermore, dose modification
was frequently used for patients who developed grade 3
peripheral neuropathy (≥1 dose delay [80 %] and/or
reduction [41 %]). This approach for the management of
peripheral neuropathy led to longer treatment duration,
and ultimately, greater treatment exposure, which likely
influenced survival outcomes. Collectively, these results
underscore the importance of AE management through
dose modification.
This subanalysis revealed that among patients who re-
ceived nab-P + Gem, not only were the rates of grade ≥ 3
peripheral neuropathy similar in patients treated to PD
vs AEs (19 % vs 21 %, respectively), but so were the rates
of grade ≥ 3 neutropenia (39 % vs 40 %) and
thrombocytopenia (13 % vs 14 %). Thus, grade ≥ 3 AEs
were no less likely in patients who discontinued due to
PD than in those who discontinued due to AEs, which
may further underscore the importance of managing
toxicity to maximize treatment duration.
Analysis of treatment effect by ORR is a direct measure-
ment of antitumour activity and, unlike OS, which can be
confounded by subsequent therapies, improvements in
ORR can be directly attributed to the ongoing treatment
[24]. Progression-free survival encompasses time to
disease progression or death [24] and represents an
important aspect of palliative treatment pancreatic cancer.
Patients treated to AEs in the absence of PD still experi-
enced treatment benefit, as evidenced by ORR and PFS
analyses, which suggests that management of AEs before
the need for discontinuation may have prolonged treat-
ment and potentially increased survival. The shorter OS
in patients treated to AEs is likely due to the shorter treat-
ment duration and infrequent use of subsequent therapies
among patients in this cohort. It also remains unanswered
whether any of these patients could have resumed therapy
outside of a protocol requirement, in which strict rules
apply for AE management and treatment discontinuation.
Baseline characteristics were uninformative regarding
identification of patients who may have developed
treatment-limiting AEs during therapy. Compared with
the other cohorts, fewer patients treated to AEs had a
previous Whipple procedure, indicating a more advanced
disease stage at diagnosis for these patients. Among
patients who were treated until AEs, those in the nab-P +
Gem arm were older while those in the Gem arm had a
greater metastatic burden compared with those in the
treatment-to-PD cohort as well as the ITT population.
However, at baseline, the performance status of these
patients was similar to that of the ITT population. At this
point, whether these imbalances influenced survival
outcomes is speculative. A future biomarker analysis mayprovide information regarding which patients are likely to
benefit from treatment vs develop unacceptable AEs.
Historically, treatment beyond first line has been an op-
tion for a subset of patients with metastatic pancreatic
cancer [25, 26]. Several randomized phase 2 clinical trials
have explored second-line chemotherapy use in patients
with metastatic pancreatic cancer [27–30]. Patients en-
rolled in these trials were all previously treated with Gem
or Gem-based regimens, and efficacy results were modest.
The current analysis, although not specifically designed to
test this hypothesis, shows that, in the treatment-to-PD
cohort, OS was numerically longer among patients who
received a subsequent therapy compared with those who
did not, regardless of treatment arm. The longest OS was
achieved by those who received first-line nab-P + Gem
followed by a subsequent therapy. A hypothetical explan-
ation might be that first-line treatment with nab-P + Gem
reduced tumor burden, which decreased cancer-related
symptoms and ultimately allowed greater use of second-
line therapies. These types of comparisons must be inter-
preted cautiously given the possibility of differences in pa-
tient characteristics, such as performance status, at the
end of first-line treatment. However, > 50 % of patients
who were treated to PD were able to receive subsequent
therapy, which supports the suitability of nab-P + Gem as
a first-line treatment for metastatic pancreatic cancer.
Conclusions
The results presented herein emphasize that first-line treat-
ment with nab-P +Gem can be optimized for maximum
treatment benefit. As revealed by previous subanalyses of
the MPACT trial, effective AE management (ie, by treat-
ment delay or dose reduction) allows for longer treatment
duration, which, in turn, increases treatment exposure [22,
23]. Therefore, physicians should pay close attention to and
promptly address AEs, when possible, to allow treatment to
PD. This MPACT subanalysis reveals that most patients
treated to PD were able to achieve adequate treatment ex-
posure while managing AEs, which translated to improved
disease control and longer survival.
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